The prevalence of hypogonadism is an increasing problem that affects increasingly more men of reproductive age. With the mainstay of hypogonadal treatment involving testosterone therapy (TTh), the fertility potential of many of these men must be investigated and considered accordingly. There exist multiple treatments for the recovery of anabolic steroid-induced hypogonadism, including gonadotropin replacement therapy to induce both spermatogenesis as well as intratesticular testosterone production. The use of follicular stimulating hormone (FSH) has been reported to decrease the time to recovery of spermatogenesis in anabolic steroid-induced azoospermia. A new formulation of testosterone in the form of tri-daily applied intranasal testicular gel mimics gonadotropin releasing hormone (GnRH) pulsatile release of luteinizing hormone (LH) to promote production of testosterone and decreases feedback inhibition of spermatogenesis. Additionally, immature testicular tissue transplant may aid in the fertility preservation for patients anticipating significant suppression of spermatogenesis.

Spermatogenesis, Anabolic, Testosterone, Hypogonadism, Follicle stimulating hormone, Enclomiphene